Gyre Therapeutics (NASDAQ:GYRE) Trading Down 11.4% on Disappointing Earnings

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares traded down 11.4% on Thursday after the company announced weaker than expected quarterly earnings. The stock traded as low as $7.14 and last traded at $7.1250. 68,431 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 89,588 shares. The stock had previously closed at $8.04.

The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. The firm had revenue of $22.52 million during the quarter, compared to analysts’ expectations of $31.61 million.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Wall Street Zen cut Gyre Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Hedge Funds Weigh In On Gyre Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of Gyre Therapeutics by 28.6% in the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after buying an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the period. Millennium Management LLC bought a new position in Gyre Therapeutics in the 3rd quarter worth $267,000. State Street Corp increased its stake in Gyre Therapeutics by 10.7% in the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of Gyre Therapeutics during the third quarter worth about $111,000. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Price Performance

The firm has a 50-day moving average of $7.61 and a 200-day moving average of $7.70. The stock has a market cap of $686.20 million, a PE ratio of 708.31 and a beta of 2.03.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.